enGene Therapeutics Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022
Selling, General & Admin	33.83	28.69	23.98	9.6	3.96
Research & Development	98.75	94.48	38.32	16.46	15.47
Total Operating Expenses	132.58	123.17	62.3	26.06	19.43
Operating Income	-132.58	-123.17	-62.3	-26.06	-19.43
Interest Income	6.95	9.43	10.41	1.12	0.13
Interest Expense	-0.32	-2.99	-2.8	-4.95	-1.42
Other Non-Operating Income (Expense)	0.18	0.57	0.48	-91.44	4.26
Total Non-Operating Income (Expense)	5.47	5.86	7.14	-73.84	-5.01
Pretax Income	-127.11	-117.3	-55.16	-99.9	-24.44
Provision for Income Taxes	-0.26	-	-0.02	0.02	0.02
Net Income	-126.85	-117.3	-55.14	-99.92	-24.46
Net Income Attributable to Preferred Dividends	-	-	-	4.82	4.56
Net Income to Common	-126.85	-117.3	-55.14	-104.74	-29.02
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	60	51	38	1	1
Shares Outstanding (Diluted)	60	51	38	1	1
Shares Change	25.64%	35.30%	5355.08%	5.72%	-
EPS (Basic)	-4.15	-2.29	-1.46	151.22	44.30
EPS (Diluted)	-4.15	-2.29	-1.46	151.22	44.30
EPS Growth	-	-	-	241.35%	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022
Free Cash Flow	-111.39	-100.72	-49.21	-25.06	-17.75
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-1.86	-1.97	-1.30	-36.18	-27.09
EBITDA	-131.91	-122.66	-61.97	-25.89	-19.19
EBIT	-132.58	-123.17	-62.3	-26.06	-19.43
Effective Tax Rate	0.20%	0.00%	0.03%	-0.02%	-0.09%

SEC Filings: 10-K · 10-Q